TITLE

Irritable Bowel Syndrome—Type Symptoms in Patients With Inflammatory Bowel Disease: A Real Association or Reflection of Occult Inflammation?

AUTHOR(S)
Keohane, John; O'Mahony, Caitlin; O'Mahony, Liam; O'Mahony, Siobhan; Quigley, Eamonn M.; Shanahan, Fergus
PUB. DATE
August 2010
SOURCE
American Journal of Gastroenterology;Aug2010, Vol. 105 Issue 8, p1789
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES:Do gastrointestinal symptoms in patients with inflammatory bowel disease (IBD) in apparent remission reflect the coexistence of irritable bowel syndrome (IBS) or subclinical inflammation? The aims of this study were as follows: (i) to prospectively determine the prevalence of IBS symptoms in IBD patients in remission; and (ii) to determine whether IBS symptoms correlate with levels of fecal calprotectin.METHODS:Remission was defined by physician assessment: Crohn's disease (CD) activity index ≤150 and ulcerative colitis disease activity index ≤3, and serum C-reactive protein <10, while off corticosteroids or biologics. Quality of life (QOL) (by inflammatory bowel disease questionnaire), the hospital anxiety and depression scale (HAD), and fecal calprotectin were measured.RESULTS:Rome II criteria for IBS were fulfilled in 37/62 (59.7%) of CD patients and by 17/44 (38.6%) of those with ulcerative colitis (UC). However, fecal calprotectin was significantly elevated above the upper limit of normal in both IBD patient groups, indicating the presence of occult inflammation. Furthermore, calprotectin levels were significantly higher in CD and UC patients with criteria for IBS than in those without IBS-type symptoms. QOL scores were lower and HAD scores higher among UC patients with IBS symptoms in comparison to those who did not have IBS symptoms.CONCLUSIONS:IBS-like symptoms are common in patients with IBD who are thought to be in clinical remission, but abnormal calprotectin levels suggest that the mechanism in most cases is likely to be occult inflammation rather than coexistent IBS.
ACCESSION #
52703083

 

Related Articles

  • Alteration of GI symptoms in a cow with Johne disease by the dietary organosulfur, 2-mercaptoethanol. Click, Robert E. // Virulence;Oct2012, Vol. 3 Issue 6, p543 

    Sub-phenotypes of inflammatory bowel disease (IBD)--Crohn disease, ulcerative colitis and some cases of irritable bowel syndrome--are generally considered a consequence of gastrointestinal inflammation of unknown etiology. Conventional therapy and more recently biologic agents, all with varying...

  • PERSONALITY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME AND INFLAMMATORY BOWEL DISEASES. Tkalcic, Mladenka; Hauser, Goran; Pletikosic, Sanda; Ştimac, Davor // Clujul Medical;Dec2009, Vol. 82 Issue 4, p577 

    This is a comparative study of some presonality factors in two chronic gastrointestinal conditions: Iritable bowel syndrome (IBS) and Inflammatory bowel disease (IBD). A group of 150 outpatients aged 19 to 75 (Mean=45.50, SD=14.66) were investigated: 34 patients with ulcerative colitis, 30...

  • PSYCHOLOGICAL ASPECTS AND PSYCHOTHERAPY OF INFLAMMATORY BOWEL DISEASES AND IRRITABLE BOWEL SYNDROME IN CHILDREN.  // Biomedical Papers of the Medical Faculty of Palacky University i;2010, Vol. 154 Issue 4, p307 

    No abstract available.

  • Kalprotektin ve stolici. Kamenář, D.; Špičák, J. // General Practitioner / Prakticky Lekar;Nov2011, Vol. 91 Issue 11, p665 

    Calprotectin is a calcium-binding protein contained in neutrophils. Inflammatory damage of the intestinal mucosa causes an influx of neutrophils into the intestinal lumen, after which increased calprotectin levels can be measured in stools. Calprotectin in faeces is a good marker of inflammation...

  • IBS vs. IBD and other tummy aches. Moore, Elaine // MLO: Medical Laboratory Observer;May2007, Vol. 39 Issue 5, p12 

    The article examines the difference between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), which is often confused with celiac disease and other enteropathies. IBS is a common functional gastrointestinal disorder that causes increased contractions or spasms of the colon or...

  • Identification of a Prodromal Period in Crohn's Disease But Not Ulcerative Colitis. Pimentel, Mark; Chang, Michael; Chow, Evelyn J.; Tabibzadeh, Siamak; Kirit-Kiriak, Viorelia; Targan, Stephan R.; Lin, Henry C. // American Journal of Gastroenterology;Dec2000, Vol. 95 Issue 12, p3458 

    OBJECTIVES: Irritable bowel syndrome, a common gastrointestinal diagnosis, has not been clearly studied in inflammatory bowel disease. Some of the residual symptoms in subjects treated with Crohn's disease and ulcerative colitis are thought to be related to irritable bowel syndrome. The aims of...

  • Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome. MING-HUI CHANG; JEN-WEI CHOU; SHAN-MING CHEN; MING-CHANG TSAI; YU-SHU SUN; CHUN-CHE LIN; CHING-PIN LIN // Molecular Medicine Reports;2014, Vol. 10 Issue 1, p522 

    The present study aimed to investigate faecal calprotectin as a diagnostic marker to differentiate between patients with inflammatory bowel disease (IBD) and those with irritable bowel syndrome (IBS). A total of 20 healthy control subjects, 26 patients with IBS and 58 patients with IBD,...

  • Prodromal irritable bowel syndrome may be responsible for delays in diagnosis in patients presenting with unrecognized Crohn's disease and celiac disease, but not ulcerative colitis. Barratt, S.; Leeds, J.; Robinson, K.; Lobo, A.; McAlindon, M.; Sanders, D.; Barratt, S M; Leeds, J S; Lobo, A J; McAlindon, M E; Sanders, D S // Digestive Diseases & Sciences;Nov2011, Vol. 56 Issue 11, p3270 

    Introduction: We aimed to determine the prevalence and duration of prodromal periods in patients with celiac disease and inflammatory bowel disease (Crohn's disease and ulcerative colitis). Furthermore, we explored to what extent vague abdominal symptoms consistent with both...

  • The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Klotz, U. // European Journal of Clinical Pharmacology;Aug2000, Vol. 56 Issue 5, p353 

    Objective: To discuss the pharmacological properties of aminosalicylates and their potential value in the treatment of chronic inflammatory bowel disease (IBD). Methods: A review of clinical studies on the pharmacokinetics and mode of action of aminosalicylates is provided. In addition, the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics